Ligand Pharmaceuticals (LGNDZ) Short-term Investments (2016 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed Short-term Investments for 16 consecutive years, with $558.6 million as the latest value for Q4 2025.
- Quarterly Short-term Investments rose 203.82% to $558.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $558.6 million through Dec 2025, up 203.82% year-over-year, with the annual reading at $558.6 million for FY2025, 203.82% up from the prior year.
- Short-term Investments hit $558.6 million in Q4 2025 for Ligand Pharmaceuticals, up from $525.1 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $558.6 million in Q4 2025 to a low of $11.1 million in Q3 2024.
- Historically, Short-term Investments has averaged $221.3 million across 5 years, with a median of $186.4 million in 2022.
- Biggest five-year swings in Short-term Investments: crashed 93.5% in 2024 and later skyrocketed 4617.02% in 2025.
- Year by year, Short-term Investments stood at $321.6 million in 2021, then crashed by 48.11% to $166.9 million in 2022, then decreased by 11.69% to $147.4 million in 2023, then increased by 24.77% to $183.9 million in 2024, then soared by 203.82% to $558.6 million in 2025.
- Business Quant data shows Short-term Investments for LGNDZ at $558.6 million in Q4 2025, $525.1 million in Q3 2025, and $177.4 million in Q2 2025.